Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
187
Recruiting, industry sponsors, Cardiovascular and metabolic, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting187
- Completed2,126
187 trials
Showing 1 to 25, recently updated first.
Atrium TherapeuticsIndustry
NCT07738107 · 37 participants (planned) · Start Sep 14, 2026 · Primary completion May 2028
Drug: ATR 1072 · For: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic and 1 more
Sites: Kansas City, Missouri; Houston, Texas
- GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)Recruiting
Eddingpharm (Zhuhai) Co., Ltd.Industry
NCT07738341 · 270 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 1, 2029
Drug: GB268; Nab-Paclitaxel and 2 more · For: Breast Cancer (Locally Advanced or Metastatic)
Sites: Beijing, China
- A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881887 · 617 participants (planned) · Start Oct 22, 2026 · Primary completion Mar 2029
Drug: LY4167586; Placebo · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Rogers, Arkansas; Anaheim, California; Los Alamitos, California · 15 sites in all
- A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise HealthyPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07915245 · 108 participants (planned) · Start Nov 6, 2026 · Primary completion Oct 2028
Drug: LY4247147; LY4247147 and 1 more · For: Obesity; Overweight
Sites: Lenexa, Kansas; Salt Lake City, Utah; Singapore, Singapore
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07845578 · 60 participants (planned) · Start Sep 25, 2026 · Primary completion Sep 11, 2027
Drug: Semaglutide; Placebo semaglutide and 1 more · For: Obesity; Overweight
Sites: Graz, Austria
- A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06945406 · 124 participants (planned) · Start May 16, 2025 · Primary completion Jul 2027
Drug: LY4057996 SC; LY4057996 IV and 6 more · For: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sites: Neuss, Germany
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT07938515 · 32 participants (planned) · Start Nov 2, 2026 · Primary completion Dec 12, 2026
Drug: DA-302168S · For: Obesity & Overweight
Sites: Suzhou, China
- A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityPivotal-lookingRecruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07243171 · 126 participants (planned) · Start Nov 18, 2025 · Primary completion Jan 5, 2027
Drug: ecnoglutide tablets; placebo with matching dosage and 2 more · For: Overweight and/or Obesity; Weight Management
Sites: Beijing, China
Suzhou Siran Biotechnology Co.,Ltd.Industry
NCT07479862 · 40 participants (planned) · Start Apr 16, 2026 · Primary completion Apr 24, 2028
Drug: SA030 Injection; Matching Placebo · For: Obese; Overweight; T2DM (Type 2 Diabetes Mellitus)
Sites: Brisbane, Australia; Adelaide, Australia
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07624071 · 88 participants (planned) · Start Jun 4, 2026 · Primary completion Dec 14, 2027
Drug: ALN-6222; Placebo · For: Obesity
Sites: Mount Royal, Canada
Novartis PharmaceuticalsNovartis (NVS)
NCT07465653 · 12 participants (planned) · Start Mar 18, 2026 · Primary completion Dec 8, 2026
Drug: HJB647 low dose; HJB647 high dose · For: Heart Failure With Reduced Ejection Fraction
Sites: Bradenton, Florida; Inverness, Florida; Jacksonville, Florida · 7 sites in all
- A Study to Evaluate ALN-2232 in Participants With ObesityPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07463846 · 156 participants (planned) · Start Mar 2, 2026 · Primary completion Apr 28, 2027
Drug: ALN-2232; Placebo and 1 more · For: Obesity
Sites: Mount Royal, Canada
AstraZenecaAstraZeneca (AZN)
NCT07024823 · 192 participants (planned) · Start Jun 9, 2025 · Primary completion Jan 29, 2027
Drug: AZD4248; Placebo and 4 more · For: Chronic Kidney Disease
Sites: Glendale, California; Chicago, Illinois; Ann Arbor, Michigan · 5 sites in all
- A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With HypertensionRecruiting
CRISPR Therapeutics AGIndustry
NCT07758634 · 69 participants (planned) · Start Sep 25, 2026 · Primary completion Jul 1, 2028
Drug: CTX340; Placebo · For: Hypertension
Sites: Jacksonville, Florida; Orlando, Florida; Port Orange, Florida · 11 sites in all
COUR Pharmaceutical Development Company, Inc.Industry
NCT06783309 · 72 participants (planned) · Start May 12, 2025 · Primary completion Aug 2027
Drug: CNP-103; Placebo · For: Type 1 Diabetes Mellitus; T1D; T1DM and 7 more
Sites: Tucson, Arizona; Newport Beach, California; San Diego, California · 45 sites in all
Madrigal Pharmaceuticals, Inc.Industry
NCT07830758 · 90 participants (planned) · Start Oct 16, 2026 · Primary completion Nov 2027
Drug: Resmetirom; Placebo · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis; Heart Failure With Preserved Ejection Fraction (HFPEF)
Sites: Peoria, Arizona; Oxnard, California; Fort Myers, Florida · 5 sites in all
- A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 DiabetesPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07896109 · 121 participants (planned) · Start Oct 22, 2026 · Primary completion Jul 26, 2028
Drug: NNC9836-0001; Placebo (NaCl) · For: Diabetes Mellitus, Type 2
Sites: Neuss, Germany
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07587710 · 35 participants (planned) · Start May 13, 2026 · Primary completion Dec 1, 2027
Drug: NNC0487-0111 · For: Overweight; Obesity
Sites: Bratislava, Slovakia; Malacky, Slovakia
- A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07511205 · 104 participants (planned) · Start Mar 30, 2026 · Primary completion Apr 9, 2027
Drug: AZD1043 · For: Healthy Participants; Obesity
Sites: Glendale, California; Brooklyn, Maryland; Harrow, United Kingdom
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07588100 · 30 participants (planned) · Start Jun 18, 2026 · Primary completion Jan 20, 2028
Drug: RO7663498 · For: Diabetic Retinopathy
Sites: Glendale, California; Oak Forest, Illinois; Columbus, Ohio · 4 sites in all
- Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaPivotal-lookingRecruiting
Biocon Biologics UK PLCIndustry
NCT07476326 · 120 participants (planned) · Start Sep 9, 2026 · Primary completion Aug 16, 2027
Drug: Bmab1700; Opdivo · For: Melanoma
Sites: Bento Gonçalves, Brazil; Ijuí, Brazil; Pará, Brazil · 46 sites in all
- A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or ObesityPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07876531 · 144 participants (planned) · Start Oct 16, 2026 · Primary completion Apr 6, 2027
Drug: Berobenatide · For: Overweight and/or Obesity; Healthy Participants
Sites: Anaheim, California
- Study of UBT37034 InjectionRecruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07873645 · 40 participants (planned) · Start Oct 15, 2026 · Primary completion Aug 2027
Drug: UBT37034; Placebo · For: Overweight , Obesity
Sites: Changsha, China
- A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese SubjectsPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT07102251 · 126 participants (planned) · Start Sep 21, 2025 · Primary completion Dec 31, 2026
Drug: HEC-007 injection; Placebo and 2 more · For: Healthy Subjects
Sites: Hefei, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.